A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics

/in ,

A potential disease-modifying treatment for osteoarthritis from Cynata Therapeutics Osteoarthritis is a chronic inflammatory joint disease that causes pain and disability, affecting over two million people in Australia and over 500 million people worldwide. Currently, there are no approved disease-modifying therapies for osteoarthritis, with treatment options limited to symptom management. Cynata is developing CYP-004, our Cymerus™ off-the-shelf iPSC-derived […]

Read more

Cynata Therapeutics release its Appendix 4E and Annual Report

/in ,

Cynata Therapeutics release its Appendix 4E and Annual Report Cynata Therapeutics has released its Appendix 4E and Annual Report, reflecting a year of strong momentum and significant progress across its clinical pipeline. As Independent Chair, Dr Geoff Brooke states, “Cynata is entering what I believe will be the most pivotal year in our history. Within […]

Read more

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease

/in ,

Phase 2 clinical trial of CYP-001 for treating high risk acute graft-versus-host disease Earlier this week at the Australia and New Zealand Cellular Therapy and Transplant Conference (ANZTCT), Dr Ashleigh Scott of Cynata Therapeutics presented their latest clinical progress: a Phase 2 randomised, double-blind, placebo-controlled trial of CYP-001 for high-risk acute graft-versus-host disease (HR-aGvHD). CYP-001, manufactured with its proprietary Cymerus® technology, delivers consistent, high-quality […]

Read more

Scalable MSC platform enabling next wave of stem cell therapies with Dr. Kilian Kelly of Cynata Therapeutics

/in ,

Scalable MSC platform enabling next wave of stem cell therapies with Dr. Kilian Kelly Cynata Therapeutics Cynata CEO Dr Kilian Kelly recently joined Karen Jagoda on the Empowered Patient Podcast to discuss “Scalable MSC Platform Enabling Next Wave of Stem Cell Therapies.” In this episode, Dr Kelly explores how our proprietary Cymerus™ technology is revolutionising […]

Read more

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine

/in ,

How Cynata Therapeutics is unlocking the power of iPSCs to transform regenerative medicine Cynata Therapeutics, a Melbourne, Australia-based regenerative medicine company, is pioneering a new era in cell therapy with its Cymerus platform. Built on the foundation of induced pluripotent stem cell (iPSC) technology, Cynata’s approach offers a transformative alternative to traditional mesenchymal stem cell […]

Read more

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease

/in ,

Promising efficacy data in preclinical studies of Cymerus MSCs in heart disease Melbourne, Australia; 7 April 2025 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”,or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, today announced positive efficacy data observed in preclinical studies conducted with Cynata’s Cymerus™ iPSC[1]-derived MSCs[2] in models of ischaemic heart disease. MSCs […]

Read more

US FDA Clears IND for Cynata’s Phase 2 Clinical Trial of CYP-001 in GvHD

/in ,

Link to full article Key Highlights: • US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company • Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with […]

Read more

Cynata Advances Clinical Trial in Diabetic Foot Ulcers

/in

Link to full article Melbourne, Australia; 21 April 2022: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinicalstage biotechnology company specialising in cell therapeutics, is pleased to announce enrolment of initial patients in a clinical trial of CYP-006TK as a potential treatment for diabetic foot ulcers (DFU). Subjects are now being followed as planned for […]

Read more

Cynata Receives Decision to Grant a Patent in Japan

/in ,

27 January 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application […]

Read more

Cynata and FUJIFILM Cellular Dynamics Execute Strategic Manufacturing Agreement

/in ,

29 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from induced pluripotent […]

Read more